glp-1 class action in louisiana Will Blue Pay for GLP-1s for Weight Loss? The GLP-1 RA Legal Timeline:

52-WEEK RESULTS Statistically significant A1C control vs Januvia 2,4* Sustainable A1C control demonstrated at 52 weeks *Endpoint not adjusted for multiplicity

(2024) 7:e2436783

Primary candidates for MariTide People living with obesity who might benefit include: Adults with BMI 30 kg/m (obesity) Those with BMI 27 kg/m with obesity-related conditions Patients with both obesity and type 2 diabetes People seeking long-term weight control with less frequent dosing Specific health conditions Phase 3 trials will study MariTide in patients with: Atherosclerotic cardiovascular disease (blocked arteries) Heart failure Kidney disease Obstructive sleep apnea (breathing problems during sleep) High blood pressure MariTide availability Right now, MariTide is progressing through Phase 3 trials as part of Amgens MARITIME program

It is lasting health and balance

We extracted GLP-1 RAs (exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, tirzepatide) and DPP-4 inhibitors (linagliptin, alogliptin, saxagliptin, sitagliptin) from Q1 2013 to Q1 2024 for all AEs classified as biliary disorders (SMQ), with the drug role selecting the primary suspect drug (PS)

Supplementary Materials The following are available online at Figure S1: Postprandial glucose of three participants with prediabetes in the dose study, Table S1: Nutrient and polyphenol content in the MO dry leaf powder, Table S2: Primers used in qPCR gut microbiota analysis, Table S3: Anthropometrical values at basal and end-of-intervention time points, Table S4: Energy and nutrient intakes at the three study visits in each group